Piper Sandler analyst Matt O'Brien maintained an Overweight rating and $70 price target on Tandem Diabetes Care (TNDM) following a presentation of the results of Tandem's Control-IQ study in pediatric patients that showed an increase in time in range to 67% from 53% against a 4 percentage point increase in the control arm. The analyst called it a "positive update" and said the data made for a "solid case to the FDA to expand the label for the technology down to 6 years of age from 14, "which should only accelerate share-taking by the company going forward."